Persistent negative free cash flow, highlighted by a $10.7 million outflow in 2026Q1, underscores a total reliance on external financing to fund ongoing clinical development.
| Cash from Operations | -24.09M | -20.45M | -24.67M | -32.02M | -39.03M | -30.26M | -17.7M | -8.57M | -10.31M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 14.41% | 17.09% | 22.96% | 17.94% | -28.97% | -70.91% | -106.57% | 16.89% | - |
| Net Income | -184.46M | -21.09M | -30.16M | -34.1M | -48.59M | -36.79M | -20.1M | -16.74M | -13.04M |
| Depreciation & Amortization | 135K | 139K | 1.32M | 1.35M | 1.35M | 685K | 209K | 73K | 44K |
| Stock-Based Compensation | 13.71M | 1.27M | 3.13M | 4.45M | 5.81M | 5.66M | 1.49M | 0 | 1.19M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 19K | 0 | 0 | 0 |
| Other Non-Cash Items | 147.25M | 811K | 1.52M | 603K | 1.4M | 57K | 1.09M | 4.63M | 349K |
| Working Capital Changes | -733K | -1.59M | -489K | -4.33M | 1.01M | 117K | -397K | 3.47M | 1.49M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.33M | 233K | -445K | -2.33M | 2.02M | -1.43M | 335K | 2.34M | 931K |
| Cash from Investing | -18.86M | 19.77M | 22.44M | 38.41M | 49.95M | -143.12M | -1.4M | -53K | -31K |
| Capital Expenditures | -22K | -16K | -146K | -180K | -321K | -2.03M | -1.21M | -53K | -31K |
| CapEx % of Revenue | -0.45% | - | - | - | - | - | - | - | - |
| Acquisitions | 210K | 250K | 0 | 166K | 15K | 318K | -197K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 6.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 185.4M | -645K | -787K | -11.17M | -287K | 163.94M | 35.45M | 8.22M | 750K |
| Debt Issued (Net) | -579K | -648K | -811K | -761K | -629K | -255K | 526K | 8.07M | 750K |
| Equity Issued (Net) | 200.01M | 6K | 34K | -10.34M | 342K | 164.09M | 37.01M | 154K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -1K | 0 | -10.38M | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -14.03M | -3K | -10K | -76K | 0 | 109K | -2.08M | 0 | 0 |
| Net Change in Cash | 142.45M | -1.33M | -3.02M | -4.78M | 10.64M | -9.44M | 16.34M | -402K | -9.59M |
| Free Cash Flow | -24.11M | -20.47M | -24.82M | -32.2M | -39.35M | -32.28M | -18.91M | -8.62M | -10.34M |
| FCF Margin % | 497.09% | - | - | - | - | - | - | - | - |
| FCF Growth % | 0.59% | 17.52% | 22.94% | 18.16% | -21.87% | -70.72% | -119.28% | 16.63% | - |
| FCF per Share | -18.62 | -16.24 | -0.99 | -1.15 | -1.28 | -1.17 | -0.62 | -0.29 | -15.10 |
| FCF Conversion (FCF/Net Income) | 0.13x | 0.97x | 0.82x | 0.94x | 0.80x | 0.82x | 0.88x | 0.51x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 12K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Critical liquidity and clinical binary
As reported in financial statements, the persistent gap between net loss and operating cash flow, highlighted by the 2026Q1 net loss of $170.2M against an OCF of -$10.7M, suggests that non-cash adjustments and accrual accounting significantly mask the actual cash consumption rate of the business.
The divergence between accounting losses and cash outflows indicates that the company's reported net income is a poor proxy for its actual liquidity requirements. Investors should monitor the OCF/NI ratio, which remains highly volatile and reflects the lumpy nature of clinical trial expenditures rather than operational efficiency.
Based on the company's reported figures, free cash flow remains consistently negative across all observed periods, with the most recent quarterly outflow of $10.7M underscoring the firm's total reliance on external financing to sustain its ongoing research and development activities in the immuno-oncology space.
The lack of positive FCF is expected for a pre-revenue biotech, yet the trend shows no signs of stabilization as the company continues to fund its SNS-101 program. This trajectory implies that the firm's survival is entirely contingent on capital market access rather than internal cash generation.
According to recent SEC filings, working capital changes have fluctuated significantly, ranging from a $603,000 inflow in 2024Q3 to a $1.5M outflow in 2025Q2, which suggests that the timing of clinical trial payments and vendor settlements creates unpredictable swings in the company's short-term cash position.
These fluctuations in working capital appear to be driven by the timing of CRO invoices and clinical trial milestones rather than operational improvements. This volatility complicates cash forecasting and necessitates a larger liquidity buffer than the current $8.6 million cash balance provides.
As indicated by the company's financial statements, stock-based compensation remains a material non-cash expense, with $12.9M recorded in 2026Q1, which effectively subsidizes the company's operational burn but obscures the true economic cost of talent retention in a highly competitive biotechnology labor market.
While SBC preserves cash, it represents a significant dilution risk for shareholders that is not captured in the operating cash flow statement. Analysts should interpret the cash burn in conjunction with the dilutive impact of these equity-based incentives to understand the true cost of the company's R&D efforts.
Quick answers to the most common questions about buying SNSE stock.
Sensei Biotherapeutics, Inc. (SNSE) generated $-20.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Sensei Biotherapeutics, Inc. (SNSE) reported negative free cash flow of $20.5M in 2025, indicating capital requirements exceeded cash from operations.
Sensei Biotherapeutics, Inc. (SNSE) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Sensei Biotherapeutics, Inc. (SNSE) spent $0.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.